Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | LIPE | Q05469 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446647 | 1.00 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18898350 | 0.86 | LPL (0.30) | LPLLIPG | |
| SCHEMBL27978517 | 0.82 | — | — | |
| SCHEMBL17605016 | 0.80 | LPL (0.37) | LPLLIPGJAK2BTKLIPE | |
| SCHEMBL8229332 | 0.80 | LPL (0.37) | LPLLIPGP2RX7LIPE | |
| SCHEMBL29468995 | 0.80 | NOS3 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16473312 | 0.80 | LPL (0.37) | LPLLIPGJAK2BTKLIPE | |
| SCHEMBL2813914 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKLIPE | |
| SCHEMBL31046590 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKLIPE | |
| SCHEMBL1114298 | 0.80 | NOS3 (0.42) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-09-09 | — | — | US | disclosed |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIKAVATION THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250268098-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-08-21 | — | — | US | disclosed |
| US-12382827-B2 | Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same | NOVALED GMBH (DE) | 2025-08-05 | — | — | US | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070583-A1 | PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070583-A1 | PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009043884-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | PDE12, PDE5A, PDE3A | LPL 56/4885LIPG 163/4885CA1 4648/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | LPL 2325/4885LIPG 1868/4885CA1 2557/4885 |
| US-12509470-B2 | Antiviral heterocyclic compounds | NR3C1, ZC3HAV1, HAVCR2 | LPL 2470/4885LIPG 3502/4885CA1 2525/4885 |
| US-12382827-B2 | Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same | OCIAD1, AOX1, OCIAD2 | LPL 222/4885LIPG 609/4885CA1 4338/4885 |
| US-20250268098-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | MCOLN2, OPRD1, MCOLN1 | LPL 19/4885LIPG 329/4885CA1 4783/4885 |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | LPL 2970/4885LIPG 3446/4885CA1 4831/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | LPL 2019/4885LIPG 3660/4885CA1 2884/4885 |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIK3CA, PIK3C2A, PIK3R5 | LPL 704/4885LIPG 477/4885CA1 4185/4885 |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | LPL 2970/4885LIPG 3446/4885CA1 4831/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | LPL 3661/4885LIPG 2397/4885CA1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.